(NQ: )

N/A UNCHANGED

Last Price Updated: Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	-
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

June 20, 2016

Mateon Therapeutics, Inc. (Nasdaq:MATN), formerly OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications,...

OXiGENE Announces Name Change to Mateon Therapeutics

June 17, 2016

OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology indications, today announced that it has changed its name to Mateon...

Performance

More News

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

June 10, 2016

OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

May 23, 2016

Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors

May 19, 2016

OXiGENE Reports First Quarter 2016 Financial Results

May 09, 2016

Oxigene Receives Fast Track Designation From U.S. FDA for CA4P

March 30, 2016

OXiGENE Reports 2015 Financial Results

March 28, 2016

BRIEF-Oxigene announces name change to Mateon Therapeutics

June 17, 2016

OXiGENE Gets Orphan Drug Status For Its CA4P To Treat Glioma

June 10, 2016

OXiGENE (OXGN) Leaps on Study Results

May 24, 2016

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.